Advertisement

Galapagos N.V. GLPG

Set alert

Price alert · GLPG

All alert types
27.98 USD 0.00 0.00%

As of Jun 4, 11:58 AM ET

Bid
27.68 × 1
Ask
27.74 × 1
27.50 Day range 28.09
27.15 52-week range 36.24
YTD
-14.43%
1 year
-3.08%
Open
27.50
Prev close
27.98
Mkt cap
1.84B
Vol
2.38K
Avg vol
144.77K
EPS
0.00
P/E
3.91
Div yield
0.00%
More statistics
Low
27.50
High
28.09
Beta
0.30
Inst. own
22.31%
Dividend
0.00
Earnings
Aug 10, 2026

2Y chart

Chart tools
Interval

Events in this range
  • Jan 23, 2025Downgrade: Barclays · Equal-Weight → Underweight
  • Feb 14, 2025Downgrade: Morgan Stanley · Equal-Weight → Underweight
  • Apr 23, 2025Earnings: -2.47; estimate -0.23; surprise -973.91%
  • Jul 23, 2025Earnings: -1.89119; estimate -0.67; surprise -182.27%
  • Oct 21, 2025Rating: Leerink Partners · Market Perform → Outperform
  • Oct 22, 2025Rating: RBC Capital · Sector Perform → Sector Perform
  • Nov 5, 2025Earnings: -3.59271; estimate -0.2; surprise -1696.35%
  • Nov 7, 2025Rating: RBC Capital · Sector Perform → Sector Perform
  • Feb 23, 2026Earnings: 16.38; estimate 1; surprise 1538%
  • Feb 25, 2026Rating: RBC Capital · Sector Perform → Sector Perform
  • May 6, 2026Earnings: 0.25; estimate -1.27; surprise 119.69%
Signals (71)
NameDateAgo
MACD: Buy SignalApr 15, 20266 months ago
SMA: BearishMar 20, 20267 months ago
SMA: BullishMar 16, 20267 months ago
SMA: BearishMar 12, 20267 months ago
SMA: BearishMar 5, 20268 months ago
SMA: BullishMar 4, 20268 months ago
SMA: BearishMar 3, 20268 months ago
MACD: Sell SignalJan 30, 20269 months ago
SMA: BullishDec 19, 202510 months ago
SMA: BearishDec 12, 202510 months ago
SMA: BullishDec 10, 202510 months ago
MACD: Buy SignalNov 25, 202511 months ago
MACD: Sell SignalNov 18, 202511 months ago
MACD: Buy SignalNov 10, 202511 months ago
SMA: BearishOct 21, 20251 year ago
MACD: Sell SignalOct 9, 20251 year ago
RSI: OverboughtOct 3, 20251 year ago
MACD: Buy SignalSep 18, 20251 year ago
SMA: BullishSep 16, 20251 year ago
SMA: BearishSep 15, 20251 year ago
MACD: Sell SignalSep 12, 20251 year ago
MACD: Buy SignalSep 8, 20251 year ago
MACD: Sell SignalAug 6, 20251 year ago
RSI: OverboughtJul 18, 20251 year ago
RSI: OverboughtJul 10, 20251 year ago
MACD: Buy SignalJul 3, 20251 year ago
SMA: BullishJun 24, 20251 year ago
SMA: BearishJun 23, 20251 year ago
MACD: Sell SignalJun 4, 20251 year ago
RSI: OverboughtMay 28, 20251 year ago
RSI: OverboughtMay 20, 20251 year ago
SMA: BullishMay 15, 20251 year ago
MACD: Buy SignalMay 15, 20251 year ago
SMA: BearishMay 14, 20251 year ago
SMA: BullishMay 13, 20251 year ago
SMA: BullishMay 13, 20251 year ago
SMA: BearishMay 8, 20251 year ago
MACD: Sell SignalMay 8, 20251 year ago
SMA: BearishMay 6, 20251 year ago
RSI: OverboughtMay 2, 20251 year ago
SMA: BullishApr 25, 20251 year ago
SMA: BullishApr 23, 20251 year ago
MACD: Buy SignalApr 16, 20251 year ago
RSI: OversoldApr 7, 20251 year ago
SMA: BearishApr 1, 20251 year ago
MACD: Sell SignalMar 10, 20251 year ago
SMA: BullishFeb 18, 20251 year ago
RSI: OverboughtFeb 18, 20251 year ago
MACD: Buy SignalFeb 7, 20251 year ago
RSI: OversoldJan 23, 20251 year ago
RSI: OversoldJan 13, 20251 year ago
SMA: BearishJan 10, 20251 year ago
MACD: Sell SignalJan 10, 20251 year ago
SMA: BullishDec 31, 20241 year ago
MACD: Buy SignalDec 23, 20241 year ago
MACD: Sell SignalDec 19, 20241 year ago
MACD: Buy SignalNov 25, 20241 year ago
MACD: Sell SignalNov 15, 20241 year ago
MACD: Buy SignalNov 14, 20241 year ago
SMA: BearishOct 28, 20242 years ago
MACD: Sell SignalOct 24, 20242 years ago
MACD: Buy SignalOct 17, 20242 years ago
MACD: Sell SignalSep 23, 20242 years ago
RSI: OverboughtAug 27, 20242 years ago
SMA: BullishAug 23, 20242 years ago
MACD: Buy SignalAug 23, 20242 years ago
SMA: BearishAug 2, 20242 years ago
MACD: Sell SignalAug 2, 20242 years ago
SMA: BullishJul 22, 20242 years ago
RSI: OversoldJun 26, 20242 years ago
RSI: OversoldJun 10, 20242 years ago

Key statistics

Market cap
1.84B
Enterprise value
1.84B
Trailing P/E
3.91
PEG ratio
-0.10
Price / sales
1.82
Price / book
0.59
Beta
0.30
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
46.83%
Total cash
0
Total debt
0
Return on equity
16.88%

Analyst view

Price target (mean) —
Ratings (0m) 3 0 buy · 3 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Aug 10, 2026

Expected Aug 10, 2026. Consensus EPS estimate -6.24.

Earnings history

Financials — quick view

All financials
GLPG Revenue — quarterly 8.06M
2021-Q2 20212022-Q1 20222022-Q4 20222023-Q1 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
GLPG Net income — quarterly 14.49M
2021-Q2 20212022-Q1 20222022-Q4 20222023-Q1 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
GLPG EPS — quarterly 0.22
2021-Q2 20212022-Q1 20222022-Q4 20222023-Q1 20232023-Q4 20232024-Q1 20242024-Q4 20242025-Q1 20252025-Q4 20252026-Q1 2026

Earnings

GLPG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 10, 2026Jun 30, 2026-0.96723———
May 6, 2026Mar 31, 2026-1.270.25+1.52+119.69%
Feb 23, 2026Dec 31, 20251.0016.38+15.38+1,538.00%
Nov 5, 2025Sep 30, 2025-0.20-3.59-3.39-1,696.35%
Jul 23, 2025Jun 30, 2025-0.67-1.89-1.22-182.27%
Apr 23, 2025Mar 31, 2025-0.23-2.47-2.24-973.91%

Upgrades / downgrades

GLPG analyst upgrades and downgrades
DateFirmActionFromTo
Feb 25, 2026RBC CapitalmainSector PerformSector Perform
Nov 7, 2025RBC CapitalmainSector PerformSector Perform
Oct 22, 2025RBC CapitalmainSector PerformSector Perform
Oct 21, 2025Leerink PartnersupMarket PerformOutperform
Feb 14, 2025Morgan StanleydownEqual-WeightUnderweight
Jan 23, 2025BarclaysdownEqual-WeightUnderweight

About Galapagos N.V.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Sector
Healthcare
Industry
Biotechnology
Country
BE
Employees
452

News

Your note

Sign in to keep a note on GLPG — it syncs with the Stock Master app.

Institution ownership

GLPG institution ownership
Holder% heldSharesValueReported
Gilead Sciences Inc25.35%16,707,477463.30MDec 30, 2025
Tang Capital Management, LLC5.95%3,921,219108.74MDec 30, 2025
Madison Avenue Partners, LP3.36%2,213,16961.37MDec 30, 2025
EcoR1 Capital, LLC2.53%1,667,11946.23MDec 30, 2025
Ameriprise Financial, Inc.2.20%1,451,23940.24MDec 30, 2025
Prosight Management, Lp1.63%1,074,11229.79MDec 30, 2025

Fund ownership

GLPG fund ownership
Holder% heldSharesValueReported
Columbia Funds Series Trust-Columbia Overseas Value Fund1.08%714,74719.82MFeb 27, 2026
Columbia Fd.s Varbl Series TRT II-Columbia Varbl PORT. - Overseas Core0.59%385,90610.70MDec 30, 2025
iShares Trust-iShares Core MSCI EAFE ETF0.48%314,7748.73MMar 30, 2026
iShares Trust-iShares Biotechnology ETF0.41%272,4597.56MMar 30, 2026
iShares Trust-iShares MSCI EAFE Small-Cap ETF0.20%130,4243.62MMar 30, 2026
Segall Bryant & Hamill Trust-SBH Small Cap Value Fund0.14%94,1522.61MDec 30, 2025
Advertisement